China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
